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Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental
disorder in children. Over the past twenty years, research on the disease and
its characteristics and treatment options has grown exponentially. The first-line
pharmacologic treatment of ADHD is stimulants, which have a response rate of ∼70%.
With the support of four phase 3 studies involving more than 1,000 pediatric patients
6–17 years old, the FDA has approved the non-stimulant, serotonin-norepinephrine
modulating agent (SNMA) viloxazine in an extended-release capsule (viloxazine ER) for
treatment of ADHD in children aged 6–17. Viloxazine modulates serotonergic activity as
a selective 5-HT22B receptor antagonist and 5-HT2C receptor agonist and moderately
inhibits norepinephrine transporter (NET), thus blocking the reuptake of norepinephrine.
A phase 2 study by Johnson et al. found that once-daily dosing of viloxazine ER in
200, 300, or 400 mg dosages in children with ADHD for eight weeks resulted in a
statistically significant reduction of ADHD-RS-IV total score. A post hoc analysis of data
from four phase 3, randomized, placebo-controlled, double-blind, three-arm, clinical trials
by Faraone et al. found that early response to viloxazine treatment, defined as a change
in ADHD-RS-5 total score at week 2, best predicted the treatment response at week 6
[75% positive predictive power (PPP), 75% sensitivity]. Proper treatment of the symptoms
and comorbidities associated with ADHD is crucial in improving a patient’s quality of life,
cognitive function, and overall therapeutic outcomes. Viloxazine’s mechanism of action,
clinical effects, and limited side effect profile point toward the drug’s relevance in the
treatment of ADHD.
Keywords: viloxazine, ADHD, non-stimulant, neuropsychiatric disorder, pediatrics, serotonin-norepinephrine
modulating agent
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INTRODUCTION

also often presents with other comorbid psychiatric disorders,
such as major depressive disorder (MDD) and anxiety disorders
(8). Examples of clinically significant inattentiveness include
overlooking details and turning in work riddled with careless
mistakes; difficulty maintaining focus during tasks, resulting in
incomplete assignments and missed deadlines; and frequently
misplacing items like keys, wallets, or cellphones. Examples of
hyperactivity and impulsivity in ADHD include being “fidgety”
and having problems sitting still for prolonged periods of time.
Individuals may talk excessively or inappropriately, blurt out
answers, and interrupt conversations (9).

According to DSM-5, attention deficit hyperactivity disorder
(ADHD) is a “chronic, neurologically-based illness characterized
by a persistent pattern of inattention and/or hyperactivity and
impulsivity that are more inappropriate or disruptive than those
in other children of a comparable age resulting in functional
impairment in multiple settings, and these behaviors have been
present for at least six months (1).” The core symptoms of ADHD
are inattentiveness, impulsivity, and/or motor unrest, which are
symptoms also prevalent in other neuropsychological disorders,
such as conduct disorder and depression (2).
ADHD is the most common neurodevelopmental disorder
in children (3). Over the past twenty years, research on the
disease and its characteristics and treatment options has grown
exponentially (2). Though ADHD has not become any more
prevalent in the general population in recent years, the disorder
has become increasingly well-recognized, likely due to increased
recognition of the impact of ADHD on functioning, advances
in diagnostic methodology and technology, and interest from
pharmaceutical companies (2).
In 2013, the DSM-5 revised the criteria for diagnosis,
including raising the age limit for onset of qualifying symptoms
from before six years of age to before 12 years of age, requiring
the presence of symptoms in at least two settings, and requiring
five rather than six symptoms for diagnosis in patients age
17 and older (2). Despite the previous misconception, ADHD
often persists into adulthood, along with new comorbidities,
consequences, and treatment options (1).
The first-line pharmacologic treatment of ADHD
is stimulants, which have a response rate of ∼70% (2).
Amphetamine-based medications such as Adderall and Ritalin
are powerful sympathomimetic drugs and can after mood,
appetite, growth, blood pressure, pulse, and sleep patterns.
Aggressiveness, hallucinations, and increased anxiety can be
associated with the use of these medications. This is why the
use of non-stimulant medications may be a good alternative
for some patients. Any medication should be combined with
behavioral management for best effect (2). With the support of
four phase 3 studies involving more than 1,000 pediatric patients
6–17 years old, the FDA has approved the non-stimulant,
serotonin-norepinephrine modulating agent (SNMA) viloxazine
in an extended-release capsule (viloxazine ER) for treatment
of ADHD in children aged 6–17 (4). This manuscript will look
at this medication but first will look at ADHD along with its
current treatment.

Pathophysiology
ADHD is primarily related to the imbalance of
neurotransmitters,
especially
dopamine
(DA)
and
norepinephrine (NE), resulting in inattention and hyperactivity.
One leading theory specifies hypoactivity of NE and DA in
the prefrontal cortex (PFC), which is involved in attention,
formulating plans, organizing thoughts, and suppressing the
processing of irrelevant and distracting stimuli, allowing a
person to remain focused on a specific task (10). Magnetic
resonance imaging (MRI) studies have shown decreased frontal
lobe volume in individuals with ADHD, and functional MRI
(fMRI) studies have demonstrated hypoactivity (11, 12).
The caudate nucleus, corpus callosum, and cerebellar vermis
may also be decreased in volume in individuals with ADHD
(13). DA is strongly implicated in the neural circuits involved
with behavior reinforcement and reward processing in the basal
forebrain, so that DA hypoactivity may contribute to impulsivity
(19, 20).

CURRENT TREATMENT OF ADHD
ADHD is treated with pharmacological and nonpharmacological interventions, including psychotherapeutic and
dietary approaches. The two classes of psychostimulants,
methylphenidate, and amphetamine, are the first-line
pharmacological treatments for ADHD (14). Second-line
pharmacological treatments include atomoxetine, guanfacine,
and clonidine; however, these medications are less effective
than psychostimulants and thus less frequently used (15).
Methylphenidate is structurally similar to NE and DA. Thus, it
acts by binding to the monoamine transporters NET and DAT,
inhibiting NE and DA reuptake and increasing the availability of
these neurotransmitters in the synapse (14).
Amphetamines demonstrate three main mechanisms of
action. First, they also bind to monoamine transporters,
norepinephrine transporter (NET), and dopamine transporter
(DAT) to prevent the reuptake of their respective
neurotransmitters. Second, amphetamines allow trace-amine
associated receptor 1 (TAAR1) to phosphorylate the DAT
transporter, allowing for ceased transport or inversing the efflux
of dopamine. Third, amphetamines may enter presynaptic
monoamine vesicles, causing an efflux of neurotransmitters
toward the synapse (14).
Atomoxetine (otherwise known as Strattera R ) is a nonstimulant that acts as a norepinephrine reuptake inhibitor,

ADHD Presentation
ADHD characteristically presents in childhood with persistently
high levels of hyperactivity, impulsivity, and/or inattention.
ADHD places students at a particular disadvantage with
academic performance. They are often unable to process
information as quickly as their peers and are more likely
to perform poorly on standardized exams, likely related to
inattentiveness (5). The impulsivity associated with ADHD
increases the risk for unsafe behaviors, such as spontaneous
sexual behavior and motor vehicle collisions (6, 7). ADHD
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increasing the amount of norepinephrine available in the synapse
(16). Atomoxetine is commonly prescribed when stimulants are
contraindicated, such as in individuals with substance abuse
disorders, bipolar disorder, or Tourette syndrome who may be
at higher risk of mood destabilization (14). Antidepressants have
also been used to treat ADHD to increase serotonin, dopamine,
and/or norepinephrine by blocking the reuptake (16).
In terms of non-pharmacologic interventions, therapy and
cognitive training techniques also show promise in the treatment
of ADHD symptoms.
Behavioral and cognitive-behavioral therapies alter the child’s
behavior through social learning principles (17). Cognitive
training involves strengthening the patient’s working memory
and attention via schedules, social skills training, verbal selfinstruction, and problem-solving strategies.

(NRIs) (21). Viloxazine’s modulation of 5-HT and NE supports
its therapeutic relevance in treating neuropsychiatric disorders
impacted by monoaminergic transmission, such as ADHD
and depression (21). NE and DA dysregulation contribute to
inattention and deficits in executive functioning in ADHD.
Recently, 5-HT has been recognized as a potential additional
therapeutic target in ADHD, supported by rodent models,
further pointing toward viloxazine’s relevance in treating
ADHD (21).

Dosing, Pharmacokinetics, and
Pharmacodynamics
Viloxazine ER is available in 100, 150, and 200 mg capsules.
In pediatric patients aged 6–11 years of age, the recommended
starting dose is 100 mg orally once daily and can be titrated in
increments of 100 mg weekly to the maximum recommended
dosage of 400 mg once daily, depending upon patient response
and medication tolerability (20). In pediatric patients aged 12–17,
the recommended starting dose is 200 mg orally once daily for the
first week of administration and can be titrated to the maximum
daily dose of 400 mg (20).
The bioavailability of viloxazine is estimated to be ∼88%, and
the time to peak plasma concentration is 5 h for one 200 mg dose.
The drug is highly protein-bound (76–82%), and the mean halflife of the viloxazine ER is 7.02 ± 4.74 h. Viloxazine undergoes
metabolism via the cytochrome-P450 enzyme CYP2D6 and the
UDP-glucuronosyltransferase enzymes UGT1A9 and UGT2B15.
The inhibitory constant (Ki ) for viloxazine at the norepinephrine
transporter (NET) is 0.63 µM, while the half-maximal inhibitory
concentration (IC50) is 0.2 µM (23).
Patients taking drugs metabolized by the CYP1A2 enzyme
may require dosing reductions, as viloxazine is a potent
CYP1A2 inhibitor. As with other serotonergic antidepressants,
concomitant use of viloxazine within fourteen days of the
discontinuation of a monoamine oxidase inhibitor (MAOI)
is contraindicated, as administration of these drugs together
could precipitate a hypertensive crisis. Viloxazine is primarily
excreted renally as the major plasma metabolite 5-hydroxyviloxazine glucuronide, such that special dosing and titration are
crucial in patients with renal impairment (18, 20). Viloxazine
is contraindicated in patients with severe hepatic insufficiency
due to its pharmacokinetic profile (23). Coadministration of
viloxazine ER and methylphenidate, a stimulant used in treating
ADHD, does not affect the pharmacokinetic profile of either
drug, and the combination may be well-tolerated in appropriate
patient populations (24).

Viloxazine
With the support of four phase 3 trials of more than 1,000
pediatric patients, the FDA has approved the SNMA viloxazine
in an extended-release (ER) capsule for the treatment of
ADHD in children aged 6–17 (4, 18). Though not considered
a stimulant medication, viloxazine produces amphetamine-like
CNS stimulant effects without evidence of drug dependence
(18). Usually prescribed for depression, viloxazine has similar
therapeutic efficacy to imipramine and amitriptyline, without the
sedative anticholinergic or adrenergic effects typical of tricyclic
antidepressants (18). As with other antidepressants, higher rates
of suicidal thoughts and behaviors were reported in pediatric
patients treated with the drug than those treated with placebo
(19). The most common adverse reactions are somnolence,
decreased appetite, fatigue, nausea, vomiting, insomnia, and
irritability (20). Other warnings and precautions include possible
activation of mania or hypomania in patients with bipolar
disorder. Patients should use caution when operating hazardous
machinery or driving a car due to potential somnolence and
fatigue (20).

Mechanism of Action
Viloxazine is an SNMA, such that its mechanism of action (MoA)
is unique compared to those of other ADHD and depression
pharmacotherapies (21). Viloxazine modulates serotonergic
activity as a selective 5-HT22B receptor antagonist and 5-HT2C
receptor agonist and moderately inhibits NET, thus blocking
the reuptake of norepinephrine (20). The 5-HT receptors, in
general, have a variety of functions such as the modulation
of GABA, glutamate, dopamine, epinephrine/epinephrine, and
acetylcholine. It also works on many hormones including
oxytocin, prolactin, vasopressin, cortisol, corticotropin, and
substance P. In the CNS, %-HT receptors exert influence on
almost every major function including memory, cognition,
emotion, perception, mood, and even consciousness (22). The 5HT2 family in general have been targets of many psychotropic
medications, such as antidepressants, antipsychotic, anorectic,
anti-insomnia. And anxiolytic medications (22).
The only moderate inhibitory activity of viloxazine at NET
is consistent with the observed low rate of cardiac effects,
more typical of primary norepinephrine reuptake inhibitors
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Clinical Studies
A study by Nasser et al. on the effect of viloxazine ER on the
QTc interval of healthy adults (25). This study was a phase I, 14day, randomized, double-blind (except for moxifloxacin control),
3-treatment, 3-period, 6-sequence, crossover design study in
healthy adults examining the ECG effects of viloxazine ER. The
authors examined ECG and pharmacokinetic measurements,
including the effect of a supratherapeutic dose of viloxazine ER
on cardiac repolarization (OTc) in healthy adults. There was a
statistically significant negative slope (P = 0.0012) between the
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viloxazine ER (700 mg) + methylphenidate (36 mg). Active
drug amount was measured using chromatographic tandem
mass spectrometry. Safety assessments such as vitals, ECGs,
AEs, and clinical lab evaluations were assessed. For viloxazine
ER alone, the following results were obtained: Cmax 100.98%,
AUCt 98.62%, and AUC∞ 98.96%. For methylphenidate alone,
the following results were obtained: Cmax 103.55%, AUCt
106.67%, and AUC∞ 106.61%. The AEs were relatively mild,
did not cause any patient to discontinue the study, and
included dizziness, nausea, somnolence, and insomnia. Changes
in clinical lab tests, vital signs, physical exam, and suicidality were
clinically insignificant. The pharmacokinetics did not impact
the pharmacokinetics of either drug. The viloxazine ER and
methylphenidate combination for ADHD appeared to be safe
for administration with very mild side effects, such as dizziness,
nausea, somnolence, and insomnia (24).
A post hoc analysis of data from four phase 3, randomized,
placebo-controlled, double-blind, three-arm clinical trials by
Faraone et al. was performed. This hoc analysis of data from
four phase 3, randomized, placebo-controlled, double-blind, 3arm clinical trials examining how early response to viloxazine ER
predicts efficacy in pediatric patients. Treatment response was
defined as having a ≥50% reduction in ADHD-RS-5 total score
at Week 6. The CGI-score at weeks 1–3 and target dose were
also assessed. The change in ADHD-RS-5 total score at week
2 best predicted the treatment response at week 6 (75% PPP,
75% sensitivity). Of the study sample of 774 treated subjects, 342
subjects (44%) were categorized as responders to the treatment.
A patient’s ADHD-RS-5 scores at week 2 can be used to make
clinically useful predictions of response to viloxazine. The week 2
data show higher levels of PPP that do not decrease excessively as
sensitivity increases (28).
A post hoc analysis by Nasser et al. data from four trials
correlated ADHD-RS-5 and Weiss Functional Impairment
Rating Scale-Parent (WFIRS-P) scores with CGI scores. CGI
scales are more intuitive assessments that can more easily
assess the clinical implications of treatment. For the “improved”
and “very much improved” ratings on the CGI-I, there were
score improvements on the ADHD-RS-5 of ∼55 and 80%,
respectively, and improvements on the WFIRS-P of ∼40 and
70%, respectively (29).
Another study by Nasser et al. utilized ADHD-RS-5 total
score, CGI, and assessments of adverse events in adolescents
with ADHD prescribed viloxazine ER. This was a phase 3,
randomized, double-blind, placebo-controlled trial, designed to
examine the efficacy and safety of viloxazine ER 200 or 400 mg
vs. placebo in adolescents aged 12–17 with ADHD. There was
a statistically significant improvement in the ADHD-RS-5 total
score in the viloxazine ER 200 and 400 mg groups (p = 0.0232
and p = 0.0091, respectively) compared to the placebo. There
was also a statistically significant improvement in CGI-score for
both the 200 and 400 mg dose groups (p = 0.0042 and p = 0.003,
respectively) compared to placebo. There were no significant
changes found in the Conners 3-PS Composite T-score (p =
0.6854, p = 0.0518, respectively) or WFIRS-P total average score
(p = 0.2062, p = 0.0519, respectively). The most common AEs
included decreased appetite, fatigue, headache, somnolence, and

1 QtcI and viloxazine Cp and between 5-OH-VLX-gluc Cp and
1QTcI (P = 0.0007), and secondary time point analyses did not
show an effect of viloxazine ER on QtcI. The authors found that
viloxazine ER does not have an impact on cardiac repolarization
and/or another electrocardiogram (ECG) parameters, such that it
does not increase the risk for cardiac arrhythmias.
A phase 3 study by Nasser et al. measured the change
in the ADHD-Rating Scale-5 (ADHD-RS-5) total scores in
schoolchildren with ADHD prescribed viloxazine ER (26). This
was a phase 3, 6-week, randomized, double-blind, placebocontrolled trial, designed to examine the efficacy and safety
of viloxazine ER for the treatment of ADHD of school-age
children. The authors examined the primary efficacy endpoint
based on change from baseline (CFB) at end of study (EOS) in the
ADHD-RS-5 total score. 477 subjects with similar demographic
and baseline characteristics were randomized to treatment with
viloxazine ER 100 or 200 mg daily or placebo. There was a
statistically significant improvement in the ADHD-RS-5 total
score in both the viloxazine ER 100-and 200-mg/day treatment
groups compared to placebo (P = 0.0004 and P = 0.0244,
respectively). There were also improvements in the CGI-I scores
(P = 0.0020 and P < 0.0001), Conners 3-PS composite T-score (P
= 0.0003 and P = 0.0002), and WIFIRS-P Total average score (P
= 0.0019 and P = 0.0002) compared to placebo. There were also
improvements in the CGI-I scores (P = 0.0020 and P < 0.0001),
Conners 3-PS composite T-score (P = 0.0003 and P = 0.0002),
and WIFIRS-P Total average score (P = 0.0019 and P = 0.0002)
when compared to placebo. The authors found that the drug
significantly improved ADHD symptoms. Adverse events related
to treatment were mild and included headache, somnolence, and
decreased appetite.
A phase 2 study by Johnson et al. found that once-daily dosing
of viloxazine ER in 200, 300, or 400 mg dosages in children with
ADHD for eight weeks. This study was a 8-week, randomized,
double-blind, placebo-controlled trial, designed to examine the
efficacy and safety of viloxazine ER in children with ADHD. The
authors examined ADHD-RS scores, CGI-S and CGI-I scores,
and safety assessments, including lab and ECG measurements,
suicidality monitoring, and AEs. 222 participants aged 6–12 years
old with ADHD were randomized to placebo or one of the
following viloxazine ER dosage groups: 100, 200, 300, or 400
mg/day. The average ADHD-RS-IV total score decreased in all
the dosing and placebo groups. In the viloxazine ER 200, 300,
and 400 mg dosage groups, the least square (LS) mean CFB
in ADHD-RS-IV was significant (p = 0.031, 0.027, and 0.021,
respectively) compared to the placebo (27). The most frequent
AEs were somnolence, headache, and decreased appetite, and the
TEAE incidence rate was similar for all treatment groups. There
were no significant trends in vital signs, ECG results, or clinical
lab tests.
A single-center, crossover, open-label trial conducted by
Faison et al. found that the coadministration of viloxazine ER and
methylphenidate. This was a single-center, crossover, open-label
trial in healthy adults, designed to examine the pharmacokinetics
of co-administered viloxazine ER and methylphenidate. The
authors examined the pharmacokinetics of 700 mg viloxazine
ER alone, 36 mg methylphenidate alone, and combination
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TABLE 1 | Clinical safety and efficacy.
References

Groups studied and intervention

Results and findings

Conclusions

Nasser et al. (25)

Phase I, 14-day, randomized,
double-blind (except for moxifloxacin
control), 3-treatment, 3-period,
6-sequence, crossover design study
in healthy adults examining the ECG
effects of viloxazine ER.

Viloxazine ER does not have an
impact on cardiac repolarization
and/or another electrocardiogram
(ECG) parameters, such that it does
not increase the risk for cardiac
arrhythmias

Viloxazine ER was found to have no
effect on cardiac repolarization or
other ECG parameters in healthy
adults, suggesting it does not
increase the risk for cardiac
arrhythmias.

Nasser et al. (26)

A phase 3 study measured the
change in the ADHD-Rating Scale-5
(ADHD-RS-5) total scores in
schoolchildren with ADHD prescribed
viloxazine ER

Randomized to treatment with
viloxazine ER 100 or 200 mg daily
or placebo.
There was a statistically significant
improvement in the ADHD-RS-5 total
score in both the viloxazine ER
groups compared to placebo (P =
0.0004 and P = 0.0244, respectively).

Significantly improved ADHD
symptoms. Adverse events related to
treatment were mild and included
headache, somnolence, and
decreased appetite

Johnson et al. (27)

Phase 2, 8-week, randomized,
double-blind, placebo-controlled trial,
designed to examine the efficacy and
safety of viloxazine ER in children with
ADHD.

Statistically significant reduction of
ADHD-RS-IV total score and
improvement in Clinical Global
Impression – Severity and
Improvement (CGI-S and CGI-I)
scores, thus improving ADHD
symptoms.

The results were dosage-dependent,
as the children in the 400-mg/day
dose had the greatest reduction of
ADHD symptoms. Treatment was
well-tolerated.

Faison et al. (24)

Single-center, crossover, open-label
trial in healthy adults, designed to
examine the pharmacokinetics of
co-administered viloxazine ER and
methylphenidate.

At each timepoint, the combination of
viloxazine and methylphenidate did
not alter the relative bioavailability
compared to the drugs being
administered alone.
The AEs were relatively mild, did not
cause any patient to discontinue the
study, and included dizziness,
nausea, somnolence, and insomnia.
Changes in clinical lab tests, vital
signs, physical exam, and suicidality
were clinically insignificant.

It was found that the combination of
viloxazine ER (700 mg) +
methylphenidate (36 mg) was safe
and well-tolerated. The
coadministration of the drugs did not
alter the pharmacokinetics compared
to those of each drug alone.

Faraone et al. (28)

Machine learning post hoc analysis of
data from four phase 3, randomized,
placebo-controlled, double-blind,
3-arm clinical trials
Treatment response was defined as
having a ≥50% reduction in
ADHD-RS-5 total score at Week 6.

The change in ADHD-RS-5 total
score at week 2 best predicted the
treatment response at week 6 (75%
PPP, 75% sensitivity).

A patient’s ADHD-RS-5 scores at
week 2 can be used to make clinically
useful predictions of response to
viloxazine. The week 2 data show
higher levels of PPP that do not
decrease excessively as sensitivity
increases.

Nasser et al. (29)

post-hoc analyses of data from four
phase 3 trials in children/adolescents
with ADHD who were treated with
viloxazine ER.

In participants who showed
improvement, a one-level CGI-I
change was correlated with
0.2–0.5-point and 10–15 point
changes on the WFIRS-P and
ADHD-RS-5 scales, respectively. For
the “improved” and “very much
improved” ratings on the CGI-I, there
were score improvements on the
ADHD-RS-5 of ∼55 and 80%,
respectively, and improvements on
the WFIRS-P of ∼40 and 70%,
respectively.

Improvement on ADHD symptom
scales following treatment with
viloxazine ER translated into clinically
significant improvement for many
patients. These post-hoc analyses
helped create clinical benchmarks to
interpret the results of ADHD-Rs-5
and WFIRS-P via their correlation with
CGI scores in individuals with ADHD.

Nasser et al. (30)

Phase 3, randomized, double-blind,
placebo-controlled trial, designed to
examine the efficacy and safety of
viloxazine ER 200 or 400 mg vs.
placebo in adolescents aged 12–17
with ADHD.

There was a statistically significant
improvement in the ADHD-RS-5 total
score in the viloxazine ER (200 and
400 mg groups) compared to the
placebo.
The most common AEs included
decreased appetite, fatigue,
headache, somnolence, and nausea.

Viloxazine ER 200 and 400 mg doses
were efficacious and safe in
adolescents with ADHD.
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nausea. The authors concluded that the drug to be well-tolerated
and to significantly improve ADHD symptoms (30). See Table 1
for a summary of the above studies.

pharmacological option for children ages 6–17 for the treatment
of ADHD (5). Viloxazine acts as a selective 5-H22B receptor
antagonist and 5-HT2C receptor agonist and moderately inhibits
norepinephrine transporter (NET), thus blocking the reuptake of
norepinephrine (20). Viloxazine’s mechanism of action, clinical
effects, and limited side effect profile point toward the drug’s
relevance in the treatment of ADHD (21). This drug could be
especially useful in those who have co-morbid anxiety disorders
with ADHD and cannot tolerate the anxiety-increasing effects of
stimulants, which have been the mainstay of treatment. This is
a promising step forward for the treatment of ADHD in both
children and adults and can change the quality of life in those
with the disorder.

CONCLUSION
ADHD, the most common neurodevelopmental disorder
in children, characteristically presents in childhood with
persistently high levels of hyperactivity, impulsivity, and
inattention (3, 9). ADHD is largely due to the imbalance of
neurotransmitters, especially DA and NE in the PFC, leading
to inattention and hyperactivity (10). Proper treatment of the
symptoms and comorbidities associated with ADHD is crucial
in improving a patient’s quality of life, cognitive function,
and overall therapeutic outcomes (1). ADHD is treated with
pharmacological and non-pharmacological interventions,
including psychotherapeutic and dietary approaches (11).
Over the past twenty years, research on ADHD and its
characteristics and treatment options has grown exponentially,
resulting in new pharmacologic options, including viloxazine (2).
Viloxazine, an SNMA, is a recently FDA-approved non-stimulant
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